Carlos Falces

Dr. Carlos Falces

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2011 in JAMA
Verified
Journal Article
Open access
PDF file
TKTodd Kiefer
Todd Kiefer
LPLawrence Park
Lawrence Park
CTChristophe Tribouilloy
Christophe Tribouilloy
CCClaudia Cortes
Claudia Cortes
RCRoberta Casillo
Roberta Casillo
AWAndrew Wang
Andrew Wang
Infective endocarditis is associated with substantial morbidity and mortality. Several published studies have reported in-hospital mortality of 15% to 20% and 1-year mortality of 40%.1 In the United States alone, approximately 15 000 new cases of infective endocarditis are diagnosed each year.1 A variety of complications contribute to the high rates of morbidity and mortality in infective endocarditis, particularly heart failure (HF), which occurs in approximately 40% of patients.2,3 Several observational studies have shown a mortality benefit for valvular surgery in infective endocarditis complicated by HF,2 and this indication for surgery is strongly recommended in current American College of Cardiology/American Heart Association and European Society of Cardiology guidelines.4,5

1 January 2006 in Farmacia Hospitalaria
Verified
Journal Article
Open access
CCC. López Cabezas
C. López Cabezas
CFCarlos Falces
Carlos Falces
DQD. Cubí Quadrada
D. Cubí Quadrada
AAAnna Arnau
Anna Arnau
MBM. Ylla Boré
M. Ylla Boré
EPE. Homs Peipoch
E. Homs Peipoch
To assess the efficacy of a multifactorial educational intervention carried out by a pharmacist in patients with heart failure (HF). A randomized, prospective, open clinical trial in patients admitted for HF. The patients assigned to the intervention group received information about the disease, drug therapy, diet education, and active telephone follow-up. Visits were completed at 2, 6, and 12 months. Hospital re-admissions, days of hospital stay, treatment compliance, satisfaction with the care received, and quality of life (EuroQol) were evaluated; a financial study was conducted in order to assess the possible impact of the program. The intervention was performed by the pharmacy department in coordination with the cardiology unit. 134 patients were included, with a mean age of 75 years and a low educational level. The patients of the intervention group had a higher level of treatment compliance than the patients in the control group. At 12 months of follow-up, 32.9% fewer patients in the intervention group were admitted again vs. the control group. The mean days of hospital stay per patient in the control group were 9.6 (SD=18.5) vs. 5.9 (SD=14.1) in the intervention group. No differences were recorded in quality of life, but the intervention group had a higher score in the satisfaction scale at two months [9.0 (SD=1.3) versus 8.2 (SD=1.8) p=0.026]. Upon adjusting a Cox survival model with the ejection fraction, the patients in the intervention group had a lower risk of re-admission (Hazard ratio 0.56; 95% CI: 0.32-0.97). The financial analysis evidenced savings in hospital costs of euro 578 per patient that were favorable to the intervention group. Postdischarge pharmaceutical care allows for reducing the number of new admissions in patients with heart failure, the total days of hospital stay, and improves treatment compliance without increasing the costs of care.

1 September 2015 in EP Europace
Verified
Journal Article
Open access
PDF file
NCNaiara Calvo
Naiara Calvo
PRPablo Ramos
Pablo Ramos
SMSilvia Montserrat
Silvia Montserrat
EGEduard Guasch
Eduard Guasch
BCBlanca Coll-Vinent
Blanca Coll-Vinent
LMLluís Mont
Lluís Mont
The role of high-intensity exercise and other emerging risk factors in lone atrial fibrillation (Ln-AF) epidemiology is still under debate. The aim of this study was to analyse the contribution of each of the emerging risk factors and the impact of physical activity dose in patients with Ln-AF. Patients with Ln-AF and age- and sex-matched healthy controls were included in a 2:1 prospective case–control study. We obtained clinical and anthropometric data transthoracic echocardiography, lifetime physical activity questionnaire, 24-h ambulatory blood pressure monitoring, Berlin questionnaire score, and, in patients at high risk for obstructive sleep apnoea (OSA) syndrome, a polysomnography. A total of 115 cases and 57 controls were enrolled. Conditional logistic regression analysis associated height [odds ratio (OR) 1.06 [1.01–1.11]], waist circumference (OR 1.06 [1.02–1.11]), OSA (OR 5.04 [1.44–17.45]), and 2000 or more hours of cumulative high-intensity endurance training to a higher AF risk. Our data indicated a U-shaped association between the extent of high-intensity training and AF risk. The risk of AF increased with an accumulated lifetime endurance sport activity ≥2000 h compared with sedentary individuals (OR 3.88 [1.55–9.73]). Nevertheless, a history of <2000 h of high-intensity training protected against AF when compared with sedentary individuals (OR 0.38 [0.12–0.98]). A history of ≥2000 h of vigorous endurance training, tall stature, abdominal obesity, and OSA are frequently encountered as risk factors in patients with Ln-AF. Fewer than 2000 total hours of high-intensity endurance training associates with reduced Ln-AF risk.

1 August 2012 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
Jose M MiroJose M Miro
Jose M Miro
JEJosé M. Entenza
José M. Entenza
ARAna del Río
Ana del Río
Maria VelascoMaria Velasco
Maria Velasco
XCXimena Castañeda
Ximena Castañeda
AMAsuncion Moreno
Asuncion Moreno
We describe 3 patients with left-sided staphylococcal endocarditis (1 with methicillin-susceptible Staphylococcus aureus [MSSA] prosthetic aortic valve endocarditis and 2 with methicillin-resistant S. aureus [MRSA] native-valve endocarditis) who were successfully treated with high-dose intravenous daptomycin (10 mg/kg/day) plus fosfomycin (2 g every 6 h) for 6 weeks. This combination was tested in vitro against 7 MSSA, 5 MRSA, and 2 intermediately glycopeptide-resistant S. aureus isolates and proved to be synergistic against 11 (79%) strains and bactericidal against 8 (57%) strains. This combination deserves further clinical study.

3 September 2014 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
LSLaura Sanchis
Laura Sanchis
LGLuigi Gabrielli
Luigi Gabrielli
RARut Andrea
Rut Andrea
CFCarlos Falces
Carlos Falces
NDNicolas Duchateau
Nicolas Duchateau
MSMarta Sitges
Marta Sitges
Aims Pathophysiology of heart failure (HF) with preserved ejection fraction (HFPEF) remains unclear. Left atrial (LA) function has been related to HF symptoms. Our purpose is to analyse LA function in outpatients with new onset symptoms of HF. Methods and results An observational study was performed including 138 consecutive outpatients with suspected HF referred to a one-stop clinic. Final diagnosis [HF with reduced EF (HFREF), HFPEF, or non-HF] was established according to current recommendations. Echocardiography was performed in all patients. LA function was analysed using strain derived from speckle tracking in sinus rhythm patients ( n = 83). Results were analysed with ANOVA and Bonferroni statistical tests. Receiver operating characteristic (ROC) curves were constructed to investigate the predictive ability of LA parameters for the final diagnosis of HF. Patients were 75 ± 9 years and 63% women. Final diagnosis was 23.2% HFREF, 45.7% HFPEF, and 31.2% non-HF. Left ventricular strain rate showed no differences between non-HF and HFPEF groups, but both groups showed differences with the HFREF group. LA strain rate (A- and S-waves) was significantly reduced in both HF groups (without differences among them) when compared with the non-HF group. LA strain rate and indexed volume showed significant accuracy for HF diagnosis in ROC curves. Conclusions In outpatients with new-onset symptoms of HF, LA dysfunction was observed. It might be the initial mechanism in the development of symptoms in HFPEF patients. These findings support the relationship of LA dysfunction with HFPEF, suggesting that the analysis of LA function may be useful in sinus rhythm patients with new-onset dyspnoea.

10 November 2014 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
CCCatherine Chirouze
Catherine Chirouze
VFVance G. Fowler
Vance G. Fowler
DSDaniel J. Sexton
Daniel J. Sexton
GCG. Ralph Corey
G. Ralph Corey
VCVivian H. Chu
Vivian H. Chu
PMPhillipe Moreillon
Phillipe Moreillon
Background. The impact of early valve surgery (EVS) on the outcome of Staphylococcus aureus (SA) prosthetic valve infective endocarditis (PVIE) is unresolved. The objective of this study was to evaluate the association between EVS, performed within the first 60 days of hospitalization, and outcome of SA PVIE within the International Collaboration on Endocarditis–Prospective Cohort Study. Methods. Participants were enrolled between June 2000 and December 2006. Cox proportional hazards modeling that included surgery as a time-dependent covariate and propensity adjustment for likelihood to receive cardiac surgery was used to evaluate the impact of EVS and 1-year all-cause mortality on patients with definite left-sided S. aureus PVIE and no history of injection drug use. Results. EVS was performed in 74 of the 168 (44.3%) patients. One-year mortality was significantly higher among patients with S. aureus PVIE than in patients with non–S. aureus PVIE (48.2% vs 32.9%; P = .003). Staphylococcus aureus PVIE patients who underwent EVS had a significantly lower 1-year mortality rate (33.8% vs 59.1%; P = .001). In multivariate, propensity-adjusted models, EVS was not associated with 1-year mortality (risk ratio, 0.67 [95% confidence interval, .39–1.15]; P = .15). Conclusions. In this prospective, multinational cohort of patients with S. aureus PVIE, EVS was not associated with reduced 1-year mortality. The decision to pursue EVS should be individualized for each patient, based upon infection-specific characteristics rather than solely upon the microbiology of the infection causing PVIE.